Arcutis Biotherapeutics, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +9.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.09 | $0.11 | +22.2% | Beat | Q2 FY26 call |
| Q1 FY26 | not reported | $-0.09 | not reported | not reported | |
| Q4 FY25 | not reported | $0.13 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $0.06 | not reported | not reported | |
| Q2 FY25 | $-0.18 | $-0.13 | +27.8% | Beat | |
| Q1 FY25 | $-0.21 | $-0.20 | +4.8% | Beat | |
| Q4 FY24 | not reported | $-0.09 | not reported | not reported | |
| Q3 FY24 | $-0.42 | $-0.33 | +21.4% | Beat | |
| Q2 FY24 | $-0.48 | $-0.42 | +12.5% | Beat | |
| Q1 FY24 | $-0.60 | $-0.32 | +46.7% | Beat | |
| Q4 FY23 | $-0.65 | $-0.72 | -10.8% | Miss | |
| Q3 FY23 | $-0.90 | $-0.73 | +18.9% | Beat |
Back to ARQT overview · ARQT holders · ARQT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.